Steffen Koschmieder

65PUBLICATIONS
236CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyHaematological tumoursEpidemiological modelling
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (65)

|Sep 24, 2026
Selective dependency of CALR-mutant myeloproliferative neoplasms on TYK2 signaling.

|Jun 30, 2026
TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis.

|Jun 03, 2026
Type-I interferon-activated NK cells control polycythemia vera in vivo.

|Apr 29, 2026
The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.

|Nov 26, 2025
NLRP3-induced systemic inflammation controls the development of JAK2V617F mutant myeloproliferative neoplasms.

Ruth-Miriam Koerber, Calvin Krollmann, Kevin Cieslak

|Nov 24, 2025
European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis.

Monia Marchetti, Alessandro Maria Vannucchi, John O Mascarenhas

Pageof 11

Frequent Collaborators

13 joint publications

Nicolas Chatain

10 joint publications

Tim Henrik Brümmendorf

10 joint publications

Francesca Palandri

9 joint publications

Tiziano Barbui